BLRX - BioLine Rx Ltd
| Previous Close | 1.12 |
| Open | 1.14 |
| Bid | 1.02 x 1000 |
| Ask | 1.34 x 2900 |
| Day's Range | 1.11 - 1.16 |
| 52 Week Range | 0.80 - 1.38 |
| Volume | 130,926 |
| Avg. Volume | 549,469 |
| Market Cap | 118.99M |
| Beta | 0.01 |
| PE Ratio (TTM) | -4.13 |
| EPS (TTM) | -0.28 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.25 |
- Zacks•yesterday
BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.
- PR Newswire•3 days ago
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has commenced a Phase 1b/2 study for the treatment of gastric cancer with BL-8040 in combination with atezolizumab (TECENTRIQ®), Genentech's anti-PDL1 cancer immunotherapy agent. Up to 40 patients are planned to be enrolled in this multicenter, randomized, controlled, open-label study to evaluate the clinical response, safety and tolerability, as well as multiple pharmacodynamic parameters, of BL-8040 in combination with atezolizumab.
- PR Newswire•25 days ago
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration
BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of a Phase 1b/2 trial for BL-8040 in combination with atezolizumab (TECENTRIQ®), an anti-PDL1 cancer immunotherapy from Genentech, a member of the Roche Group. The trial, known as the BATTLE study (NCT03154827), will focus on the maintenance treatment of patients with intermediate and high-risk acute myeloid leukemia (AML) who have achieved a complete response (CR) following induction and consolidation therapy.
- PR Newswire•last month
BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
BioLineRx Ltd. (BLRX)(BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin, and its Chief Business Officer, David Malek, will present a company update at the 19th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace Hotel in New York City. BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology.
- Zacks•2 months ago
BioLineRx Moves a Regulatory Submission for BL-8040 Trial
BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.
- PR Newswire•2 months ago
BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization
TEL AVIV, Israel, Aug 21, 2017 /PRNewswire/ --BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. The trial, named GENESIS, is expected to commence by the end of 2017, following receipt of regulatory approvals.
- ACCESSWIRE•2 months ago
Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 10:00 ...
- PR Newswire•2 months ago
BioLineRx Reports Second Quarter 2017 Financial Results
TEL AVIV, Israel , Aug. 8, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...
- PR Newswire•3 months ago
BioLineRx to Report Second Quarter 2017 Results on August 8, 2017
Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel , August 2, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology ...
GuruFocus.com•3 months ago4 Biotech Stocks to Watch This Quarter
Biotech could easily continue to grow as long-term trends remain in place
- ACCESSWIRE•3 months ago
3 Biotech Stocks to Watch in August
CORAL GABLES, FL / ACCESSWIRE / August 1, 2017 / Biotechnology stocks have remained hot this year. Since the last pullback prior to the U.S. presidential election, shares of companies across the sector ...
- PR Newswire•3 months ago
BioLineRx Announces Additional Investment From BVF Partners L.P.
BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that BVF Partners L.P. (BVF), its largest shareholder, has entered into a definitive agreement to make an additional, direct investment of $9.6 million in BioLineRx, increasing its economic interest in the Company to 24.9%. Each unit consists of 1 ordinary share, 0.35 of a Series A warrant, and 0.35 of a Series B warrant. The Series A warrants have an exercise price of $2.00 per ordinary share and a 4-year term.
- Zacks•3 months ago
BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.
- Zacks•3 months ago
BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.
- PR Newswire•3 months ago
BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has commenced a Phase 1b/2 study for BL-8040 in combination with atezolizumab (TECENTRIQ®), Genentech's anti-PDL1 cancer immunotherapy agent, evaluating the combination in metastatic pancreatic ductal adenocarcinoma. Up to 40 patients are planned to be enrolled in this Phase 1b/2, multicenter, randomized, controlled, open-label study to evaluate the clinical response, safety and tolerability, as well as multiple pharmacodynamic parameters, of BL-8040 in combination with atezolizumab. Initially, patients will receive BL-8040 injections as priming monotherapy for five consecutive days, after which, from day 8, they will receive both BL-8040 and atezolizumab, and continue with multiple treatment cycles for up to two years or until disease progression, clinical deterioration or unacceptable toxicity.
- Insider Monkey•4 months ago
Top 10 Penny Stocks To Buy in 2017
What are the top 10 penny stocks to buy in 2017? Out of thousands of stocks that are trading at price levels below $1.00, it can be hard to identify winning picks, especially since it’s no secret that the companies behind penny stocks may be involved in scams or other shady endeavors that will cause […]
- Accesswire•4 months ago
Corporate News Blog - Concordia Announces Review of Strategic Alternatives; Views Itself on the Auction Block to Repay its $3.5 billion Debt
Research Desk Line-up: BioLine Rx Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 23, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Concordia ...
- PR Newswire•5 months ago
BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors
BioLineRx Ltd. (NASDAQ: BLRX, TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has filed a total of three regulatory submissions required to commence Phase 1b trials for BL-8040 in combination with atezolizumab (Tecentriq®), Genentech's anti-PDL1 cancer immunotherapy, for the treatment of patients with solid tumors. The trials for pancreatic, gastric and non-small cell cancer are expected to commence during the second half of 2017, after receipt of regulatory approval.
- Accesswire•5 months ago
Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 25, 2017 / Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 25, 2017 at 10:00 AM Eastern Time. ...
- PR Newswire•5 months ago
BioLineRx Reports First Quarter 2017 Financial Results
TEL AVIV, Israel, May 25, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...
- Zacks•5 months ago
BioLineRx Makes Regulatory Submission for Trial of BL-8040
BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).
- PR Newswire•5 months ago
BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML
BioLineRx Ltd. (NASDAQ: BLRX, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the filing of regulatory submissions required to commence a Phase 1b trial for BL-8040 in combination with atezolizumab (Tecentriq®), Genentech, a member of the Roche Group's anti-PDL1 cancer immunotherapy, for the maintenance treatment of patients with acute myeloid leukemia (AML) who have achieved complete response following induction therapy. This clinical study is part of BioLineRx's cancer immunotherapy collaboration with Genentech to conduct several Phase 1b studies investigating BL-8040 in combination with atezolizumab in multiple cancer indications, announced in September 2016.
- PR Newswire•5 months ago
BioLineRx to Report First Quarter 2017 Results on May 25, 2017
TEL AVIV, Israel, May 16, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its ...
- PR Newswire•6 months ago
BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
BioLineRx Ltd. (NASDAQ/TASE: BLRX, BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has met with the U.S. Food and Drug Administration (FDA) and has gained clarity on the development program and the design of a Phase 3 pivotal study for BL-8040, its robust platform for multiple oncology indications, as a novel stem cell mobilization treatment for autologous bone-marrow transplantation. Following its successful meeting with the FDA, the Company anticipates the initiation of a registrational Phase 3 trial during the second half of 2017.
